-+ 0.00%
-+ 0.00%
-+ 0.00%

Mira Pharmaceuticals Reports New Preclinical Selectivity Findings for Pain Drug MIRA-55

PUBT·11/17/2026 13:01:45
Listen to the news
Mira Pharmaceuticals Reports New Preclinical Selectivity Findings for Pain Drug MIRA-55
  • Mira Pharmaceuticals reported new preclinical findings supporting MIRA-55 as a potential non-opioid treatment for inflammatory pain.
  • Receptor screening showed selective cannabinoid activity distinct from opioid interactions, with no substantial inhibition of enzymes targeted by conventional anti-inflammatory drugs.
  • Previously reported animal studies showed greater acute pain relief than morphine, with sustained chronic pain relief comparable to celecoxib.
  • Animal studies also showed reduced inflammation without significant THC-like motor impairment.
  • MIRA-55 remains in preclinical development, targeting an Investigational New Drug application submission in the first half of 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mira Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611170800PRIMZONEFULLFEED9878859) on November 17, 2026, and is solely responsible for the information contained therein.